---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-063829"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-05-21T23:59:59+00:00"
generated_at: "2026-06-01T10:42:56.367933+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio publishes Posiphen PK comparison across species in Biomolecules

## Summary
- Publication in Biomolecules compares Posiphen pharmacokinetics across mouse, rat, dog, and human samples.
- Posiphen reaches peak plasma concentration quickly, with high brain and CSF absorption.
- Drug metabolizes into N1-norposiphen and N8-norposiphen; rapid clearance in plasma but longer retention in brain/CSF.
- Absorption, distribution, metabolism, and excretion similar in healthy volunteers and Alzheimer's/Parkinson's patients.
- CEO Maria Maccecchini states publication consolidates years of research for a holistic view of Posiphen.

## SEC filing metadata
- accession: 0001104659-24-063829
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924063829/0001104659-24-063829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924063829/tm2415055d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-063829
- JSON: https://secwatch.observer/filing/0001104659-24-063829.json
- Plain text: https://secwatch.observer/filing/0001104659-24-063829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.